ESTRO 2025 - Abstract Book

S2327

Interdisciplinary – Health economics & health services research

ESTRO 2025

In 2023, 626 patients were treated, including 329 women and 297 men, with a median age of 68 years. The primary condition was breast cancer (169 patients, 27%), followed by prostate cancer (80 patients, 12.7%), lung cancer (45 patients, 7%), and bone metastases (76 patients, 12%). The average waiting time between the first visit and simulation was 16 days, and between simulation and the start of therapy was 16.6 days, totaling 32 days. 44% of patients received conventional fractionation treatment, while 33% received hypofractionated therapy with curative intent and 33% with palliative intent. In 2024, 773 patients were treated, 147 more than the previous year, with 400 women and 373 men, and a median age of 69 years. The main tumors were similar: breast (186 patients, 24%), prostate (143, 18.5%), lung (70, 9%), and bone metastases (59, 7.7%). Waiting times slightly increased, with an average total of 34 days. 185 patients received conventional treatment, 56% received curative hypofractionated treatment, and 20% received palliative treatment. Conclusion: Hypofractionation optimizes radiotherapy resources, significantly increasing patient access without compromising care quality. It addresses treatment availability and proves cost-effective in resource-limited settings. Further research should explore long-term impacts on patient outcomes and healthcare economics with larger, varied populations.

Keywords: Hypofractionation, Cost-effectiveness